When an outbreak doesn’t wait for a 12-week platform deployment, Castor is ready. The clinical trial platform trusted by WHO, global health organizations, and life sciences companies to run large-scale infectious disease studies from outbreak response to Phase III vaccine trials.
In an outbreak, days matter. Waiting weeks or months for platform configuration, validation, and site training is not an option. Infectious disease sponsors and global health organizations need a platform that can be activated and deployed to investigators within days of protocol finalization, not months after contract signature.
Infectious disease studies often run in regions with limited digital infrastructure, variable internet connectivity, and sites that have never used a sophisticated EDC system. The platform must be accessible to a field investigator in a low-resource setting as easily as to a researcher at a major academic medical center.
Adaptive designs, common in outbreak response and vaccine research, require the ability to modify treatment arms, enrollment criteria, and data collection workflows mid-study without triggering a full re-validation cycle. A platform that requires platform downtime or lengthy change-control processes cannot serve a study where the science is moving faster than the paperwork.
A study running across 52 countries requires 52-country regulatory compliance, multiple languages, and the ability to manage data standards across jurisdictions in one platform instance. Decentralized clinical trials tools eliminate the need for dedicated in-country infrastructure for each market, but only if the platform is built for global deployment from the start.
Infectious disease is the only therapeutic area where the pace of the science is dictated by the pathogen, not the sponsor’s development timeline. Outbreak response studies need to be live in days. Adaptive trial designs need to be modified in real time. Global cohorts need to be enrolled across dozens of countries with minimal site infrastructure. Standard enterprise EDC platforms with 12-to-16-week deployment cycles and rigid configuration workflows are structurally incompatible with outbreak response research.
From outbreak activation to Phase III vaccine trials, Castor is designed for the speed, scale, and compliance that infectious disease research demands.
Castor’s SaaS electronic data capture system requires no infrastructure to stand up. 90% of all studies go live in under 4 weeks from contract to first patient in, compared to 12 to 16 weeks for legacy enterprise platforms, with no reduction in compliance or validation standards. A study can be built in as little as 5 hours. For outbreak response, Castor has been activated and deployed to investigators within days of protocol finalization. The COVID-RED study demonstrates what that speed enables at scale: Julius Clinical and Takeda launched on Castor and recruited 17,824 patients in just 15 weeks, with all screening, consent, and monitoring conducted entirely remotely.
The WHO Solidarity trial, one of the largest clinical trials in history, ran on Castor. WHO deployed Castor’s EDC to 5,000 investigators across 600 sites in 52 countries with adaptive medication allocation, real-time data visibility, and six-language support. The platform handled WHO scale without failing. It can handle yours.
Castor’s platform is available in 80+ languages, enabling site-level data entry and patient-facing workflows in the local language across all study countries without per-country software builds or separate regional instances. 24/7 multilingual patient support is available in 15 to 20 languages, with SMS and WhatsApp reminders to maintain engagement across geographically dispersed and resource-limited cohorts. All on a single platform instance.
Castor’s no-code builder allows for real-time protocol amendments without taking the database offline, an essential capability for adaptive Phase II/III infectious disease studies. Treatment arms, dosing regimens, and enrollment criteria can be modified mid-study as real-world data accumulates, without requiring a full platform re-validation cycle. For outbreak response programs where the pathogen itself can change the protocol, this is a structural requirement that legacy platforms cannot meet.
For infectious disease studies where patients cannot travel to sites due to quarantine, geography, or the nature of the illness, Castor’s DCT toolkit supports remote eConsent, BYOD eCOA solutions, telemedicine visit coordination, and remote monitoring. COVID-RED is the proof point: Julius Clinical and Takeda recruited 17,824 patients in 15 weeks with all consent and monitoring conducted entirely off-site, without a single patient needing to attend a clinical facility. Up to 95%+ ePRO compliance in decentralized infectious disease cohorts.
Full regulatory compliance across all jurisdictions: FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, HIPAA, GDPR, and ISO 27001. Multi-region hosting keeps health data within borders when required by national health authorities. Castor implements regional isolation controls that prevent data from being hosted outside the designated area, ensuring medical research data is stored exclusively in the country chosen by the global health organization. For WHO-affiliated programs, national health authority studies, and multi-country research with cross-border data flow restrictions, this is a structural necessity, not an add-on. Castor’s platform maintains greater than 99.9% historic mean uptime and has captured 830 million+ data points to date, providing the reliability and audit trail depth that emergency and outbreak response programs require. This approach to real-world evidence generation at population scale is possible because the infrastructure is designed for it from the ground up.
Data points captured on Castor to date. Greater than 99.9% historic mean uptime across studies in 160+ countries, including the world’s largest infectious disease programs during active public health emergencies. The infrastructure is proven at the scale where failure is not an option.
Source: Castor verified platform data, 2026
For one of the largest global trials in history, WHO chose Castor’s EDC over every enterprise alternative. Castor delivered adaptive medication allocation, rapid site activation, and real-time data collection across 52 countries during an active global health emergency, with six-language support throughout. No platform downtime. No data sovereignty failures.
Julius Clinical and Takeda used Castor to run a fully remote, decentralized study evaluating the Ava wearable device in an infectious disease context. Patients were screened, consented, and monitored via Castor entirely off-site. A benchmark for what biotech clinical trials can achieve when DCT is the design, not the contingency plan.
Castor powered the PRECISE study tracking COVID-19 antibody prevalence in healthcare workers in Ireland, enrolling 19,216 participants and capturing nearly 500,000 data points via ePRO. This demonstrates Castor’s capability for large-scale population surveillance and epidemiological cohort management at national scale.
Data points captured in a single national ID registry
(COVID-19 NL Registry, Castor platform data, 2026)
Castor’s SaaS platform requires no infrastructure deployment. 90% of all studies go live in under 4 weeks from contract to first patient in, compared to 12 to 16 weeks for legacy enterprise platforms. For emergency response programs, Castor has been activated and deployed to investigators within days of protocol finalization. The COVID-RED study demonstrates what that speed enables: Julius Clinical activated Castor and went on to recruit 17,824 patients in just 15 weeks, entirely via decentralized remote methods.
Yes. Castor powered the WHO Solidarity trial, one of the largest clinical trials ever conducted, with 15,000+ participants across 600 sites in 52 countries. WHO deployed Castor to 5,000 investigators with adaptive medication allocation and six-language data capture during an active global health emergency.
Yes. Castor supports protocol amendments and adaptive design changes mid-study, including modifications to treatment arms, enrollment criteria, and data collection workflows, without requiring a full platform re-validation cycle. This is critical for outbreak response studies where the protocol must evolve as real-world data accumulates.
Yes. Castor’s DCT toolkit supports remote eConsent, BYOD ePRO, and telemedicine visit coordination, enabling patients to participate from home without visiting a site. In the COVID-RED study, Julius Clinical recruited 17,824 patients in 15 weeks with all consent and monitoring conducted entirely remotely via Castor, achieving 95%+ ePRO compliance throughout.
Castor is compliant with FDA 21 CFR Part 11, ICH E6(R2) and E6(R3), EU Annex 11, GDPR, HIPAA, and ISO 27001. For national health authority programs and WHO-affiliated studies with cross-border data flow restrictions, Castor implements regional data isolation controls that keep health data within the designated country. These sovereignty controls support ADHICS compliance and similar national health data requirements.
The Castor platform is available in 80+ languages, enabling site-level data entry and patient-facing workflows in the local language across all study countries without per-country software builds or separate regional instances. 24/7 multilingual patient support is available in 15 to 20 languages, with SMS and WhatsApp reminders to maintain engagement across geographically dispersed and resource-limited cohorts. The WHO Solidarity trial used six-language data capture across 52 countries on a single platform instance.
